(Q35212563)

7 August 2017

1 reference

title

Management of diabetes mellitus and insulin resistance in patients with cardiovascular disease (English)

1 reference

7 August 2017

1 reference

Vivian A Fonseca

1

1 reference

PubMed ID

12957327

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

American Journal of Cardiology

7 August 2017

1 reference

7 August 2017

92

1 reference

7 August 2017

4A

1 reference

7 August 2017

50J-60J

1 reference

Diabetes and cardiovascular disease. The Framingham study

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Management of dyslipidemia in adults with diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Diabetes and decline in heart disease mortality in US adults.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Pathogenesis of NIDDM. A balanced overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Insulin resistance and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Consensus Development Conference on Insulin Resistance. 5-6 November 1997. American Diabetes Association

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Rationale for and role of thiazolidinediones in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effects of free fatty acids on gluconeogenesis and autoregulation of glucose production in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Free fatty acid elevation impairs insulin-mediated vasodilation and nitric oxide production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Hypertension and associated metabolic abnormalities--the role of insulin resistance and the sympathoadrenal system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Nonhypoglycemic effects of thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Risk factors for coronary heart disease in diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Nontraditional risk factors for coronary heart disease incidence among persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Hypertension in diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Etiology and prevalence of hypertension in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Insulin sensitivity and the effects of insulin on renal sodium handling and pressor systems in essential hypertensive patients.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

NIDDM and its metabolic control predict coronary heart disease in elderly subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

The association of glycemia and cause-specific mortality in a diabetic population

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Prognosis of acute myocardial infarction in diabetic and non-diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Oral antihyperglycemic therapy for type 2 diabetes: scientific review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Post-meal coagulation activation in diabetes mellitus: the effect of acarbose

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM. AD-4833 Glucose Clamp Study Group, Japan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Metabolic and additional vascular effects of thiazolidinediones.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Rosiglitazone: a review of its use in the management of type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Roles of PPARs in health and disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Hyperinsulinemia as an independent risk factor for ischemic heart disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Plasma triglyceride as a risk factor for coronary heart disease. The epidemiologic evidence and beyond

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Insulin resistance and its treatment by thiazolidinediones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Rosiglitazone reduces urinary albumin excretion in type II diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance. Effects of troglitazone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Troglitazone reduces contraction by inhibition of vascular smooth muscle cell Ca2+ currents and not endothelial nitric oxide production

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Antihypertensive effect of pioglitazone is not invariably associated with increased insulin sensitivity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Blood pressure lowering by pioglitazone. Evidence for a direct vascular effect

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Endothelium-derived nitric oxide contributes to the regulation of venous tone in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

The association between insulin resistance and endotheliopathy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

The central role of fat and effect of peroxisome proliferator-activated receptor-gamma on progression of insulin resistance and cardiovascular disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Insulin action enhancement normalizes brachial artery vasoactivity in patients with peripheral vascular disease and occult diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Inhibitory effect of troglitazone on TNF-alpha-induced expression of monocyte chemoattractant protein-1 (MCP-1) in human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Vasculo-protective effects of insulin sensitizing agent pioglitazone in neointimal thickening and hypertensive vascular hypertrophy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Improved endothelial function with metformin in type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

L-2-Oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Regulation of the Hedgehog and Wingless signalling pathways by the F-box/WD40-repeat protein Slimb

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma(PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Clinical implications of insulin resistance syndromes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

The role of strict metabolic control by insulin infusion on fibrinolytic profile during an acute coronary event in diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effect of troglitazone on fibrinolysis and activated coagulation in patients with non-insulin-dependent diabetes mellitus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Prospective study of microalbuminuria as predictor of mortality in NIDDM

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Rosiglitazone monotherapy is effective in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Expression and function of peroxisome proliferator-activated receptor-gamma in mesangial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effect of troglitazone on body fat distribution in type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Efficacy of troglitazone on body fat distribution in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Thiazolidinedione derivative improves fat distribution and multiple risk factors in subjects with visceral fat accumulation--double-blind placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Abdominal fat and insulin resistance in normal and overweight women: Direct measurements reveal a strong relationship in subjects at both low and high risk of NIDDM.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Regional adiposity and morbidity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effect of rosiglitazone on insulin sensitivity and body composition in type 2 diabetic patients [corrected].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Comparison of coronary bypass surgery with angioplasty in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation (BARI) Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Impairment of myocardial protection in type 2 diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2803%2900616-7

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0002-9149(03)00616-7

1 reference

7 August 2017

1 reference

PubMed ID

12957327